Phase I Trial of the Antivascular Agent Combretastatin A4 Phosphate on a 5-Day Schedule to Patients With Cancer: Magnetic Resonance Imaging Evidence for Altered Tumor Blood Flow

James Stevenson, Peter J. O’Dwyer, Weijing Sun et al.|Journal of Clinical Oncology|2003

Cited by 293